NEPH RSI Chart
Last 7 days
0.9%
Last 30 days
-41.1%
Last 90 days
-36.7%
Trailing 12 Months
112.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 9.7M | 10.3M | 10.2M | 10.0M |
2021 | 8.8M | 9.5M | 9.9M | 10.3M |
2020 | 0 | 0 | 0 | 8.6M |
2018 | 0 | 0 | 0 | 0 |
2017 | 2.5M | 2.8M | 3.3M | 0 |
2016 | 2.0M | 1.9M | 2.1M | 2.3M |
2015 | 1.8M | 1.9M | 1.8M | 1.9M |
2014 | 1.7M | 1.6M | 1.6M | 1.7M |
2013 | 1.8M | 2.1M | 1.9M | 1.7M |
2012 | 2.1M | 1.7M | 1.9M | 1.8M |
2011 | 2.6M | 2.5M | 2.2M | 2.2M |
2010 | 0 | 2.8M | 2.8M | 2.9M |
2009 | 0 | 0 | 0 | 2.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 13, 2024 | wexford capital lp | sold | - | - | -91,463 | - |
Mar 13, 2024 | amron arthur h | acquired | - | - | 91,463 | - |
Mar 12, 2024 | amron arthur h | bought | 17,129 | 2.4471 | 7,000 | - |
Dec 13, 2023 | amron arthur h | acquired | - | - | 9,291 | - |
Dec 13, 2023 | spandow oliver j. | acquired | - | - | 14,294 | - |
Dec 13, 2023 | lask alisa | acquired | - | - | 9,291 | - |
Dec 13, 2023 | harris joseph michael | acquired | - | - | 9,291 | - |
Dec 07, 2023 | banks robert r. jr. | bought | 39,646 | 2.2026 | 18,000 | president and ceo |
Aug 15, 2023 | banks robert r. jr. | bought | 3,206 | 1.6869 | 1,901 | president and ceo |
Aug 14, 2023 | banks robert r. jr. | bought | 148 | 1.5 | 99.00 | president and ceo |
Which funds bought or sold NEPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.35 | 340,079 | 592,733 | -% |
Feb 15, 2024 | WEXFORD CAPITAL LP | reduced | -0.13 | 7,284,820 | 12,742,200 | 2.73% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | 30,689 | 54,158 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 28.00 | 28.00 | -% |
Feb 14, 2024 | Granite Investment Partners, LLC | new | - | 38,821 | 38,821 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 40,655 | 40,655 | -% |
Feb 13, 2024 | Mesirow Financial Investment Management, Inc. | new | - | 53,225 | 53,225 | -% |
Feb 13, 2024 | ELKHORN PARTNERS LIMITED PARTNERSHIP | reduced | -29.64 | 43,000 | 110,000 | 0.08% |
Feb 13, 2024 | MORGAN STANLEY | added | 120 | 94,226 | 116,858 | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | added | 1,003 | 8,295 | 8,629 | -% |
Unveiling Nephros Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Nephros Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 197.2B | 40.1B | 34.46 | 4.92 | ||||
BDX | 71.5B | 19.5B | 56.92 | 3.67 | ||||
ALGN | 24.6B | 3.9B | 55.34 | 6.38 | ||||
BAX | 21.7B | 14.8B | 8.17 | 1.47 | ||||
MID-CAP | ||||||||
BIO | 10.1B | 2.7B | -15.85 | 3.78 | ||||
HSIC | 9.7B | 12.3B | 23.33 | 0.79 | ||||
ATR | 9.5B | 3.5B | 33.39 | 2.72 | ||||
XRAY | 6.9B | 4.0B | -51.17 | 1.74 | ||||
AXNX | 3.5B | 366.4M | -577.81 | 9.6 | ||||
PDCO | 2.5B | 6.6B | 12.8 | 0.38 | ||||
SMALL-CAP | ||||||||
AHCO | 1.5B | 3.2B | -2.26 | 0.48 | ||||
ANIK | 377.2M | 166.7M | -4.56 | 2.26 | ||||
ANGO | 233.9M | 329.5M | -16.57 | 0.71 | ||||
APYX | 47.1M | 52.3M | -2.52 | 0.9 | ||||
AEMD | 4.4M | 3.7M | -0.36 | 1.17 |
Nephros Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
Revenue | 4.9% | 2,526,500 | 2,409,000 | 2,884,000 | 2,187,000 | 2,675,000 | 2,578,000 | 2,266,000 | 2,736,000 | 2,334,000 | 2,121,000 | 1,577,000 | 2,529,000 | 1,265,000 | 1,000 | 1,000 | 306,000 | 611,000 | 916,000 | 859,000 | 734,000 | 745,500 |
Gross Profit | 98.8% | 1,515,000 | 762,000 | 1,395,000 | 1,053,000 | 1,441,000 | 1,360,000 | 1,275,000 | 1,587,000 | 1,302,000 | 1,225,000 | 895,000 | 1,491,000 | 954,000 | 952,000 | 830,000 | 467,000 | - | - | - | - | - |
Operating Expenses | 8.1% | 2,208,000 | 2,043,000 | 2,209,000 | 2,600,000 | 1,959,000 | 2,162,000 | 2,392,000 | 2,605,000 | 2,021,000 | 2,157,000 | 2,493,000 | 2,517,000 | 1,683,000 | 1,463,000 | 1,483,000 | 1,590,000 | - | - | - | - | - |
S&GA Expenses | 2.6% | 1,787,500 | 1,743,000 | 1,885,000 | 2,177,000 | 1,723,000 | 1,718,000 | 1,854,000 | 1,999,000 | 1,362,000 | 1,544,000 | 1,610,000 | 1,950,000 | 1,097,000 | 1,069,000 | 1,091,000 | 1,260,000 | - | - | - | - | - |
R&D Expenses | 42.3% | 358,500 | 252,000 | 273,000 | 372,000 | 194,000 | 395,000 | 487,000 | 556,000 | 609,000 | 751,000 | 836,000 | 563,000 | - | 352,000 | - | - | - | - | - | - | - |
EBITDA Margin | -1.1% | -0.43 | -0.42 | -0.42 | -0.44 | -0.42 | -0.43 | -0.45 | -0.48 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -25.0% | 3,000 | 4,000 | 6,000 | 7,000 | 7,000 | 10,000 | 11,000 | 13,000 | 15,000 | 22,000 | 30,000 | 43,000 | 26,000 | 32,000 | 28,000 | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | 37,000 | 7,000 | 14,000 | 21,000 | 1,000 | - | 10,000 | 11,000 | -100,000 | 4,000 | - | 3,000 | -1,795,000 | 2,000 | 2,000 | 2,000 | 9,000 |
EBT Margin | -1.5% | -0.45 | -0.45 | -0.44 | -0.47 | -0.44 | -0.46 | -0.48 | -0.52 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 73.1% | -848,000 | -3,154,000 | -1,137,000 | -1,967,000 | -922,500 | -1,222,000 | -1,126,000 | -537,000 | -759,000 | -1,012,000 | -1,657,000 | -1,098,000 | -725,000 | -566,000 | -682,000 | -1,429,000 | 1,289,000 | - | - | - | - |
Net Income Margin | -0.4% | -0.71 | -0.71 | -0.51 | -0.54 | -0.37 | -0.37 | -0.36 | -0.45 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -14.7% | -195,000 | -170,000 | -1,175,000 | -1,831,000 | -335,000 | -923,000 | -117,000 | -78,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 8.6% | 11,861 | 10,919 | 10,386 | 10,927 | 10,999 | 11,335 | 14,953 | 15,528 | 17,650 | 17,820 | 17,991 | 17,936 | 18,510 | 15,242 | 16,649 | 18,294 | 11,629 | 11,554 | 12,014 | 10,138 | 10,558 |
Current Assets | -1.2% | 8,405 | 8,506 | 7,914 | 8,324 | 8,261 | 9,118 | 11,122 | 11,657 | 13,634 | 13,621 | 14,840 | 14,667 | 15,154 | 11,755 | 13,070 | 14,809 | 8,299 | 8,117 | 8,437 | 7,172 | 8,173 |
Cash Equivalents | -6.8% | 4,307 | 4,622 | 4,060 | 3,836 | 3,634 | 3,940 | 4,179 | 5,421 | 6,973 | 7,350 | 8,278 | 8,163 | 8,249 | 5,155 | 7,046 | 8,962 | 4,166 | 3,855 | 4,318 | 3,608 | 4,581 |
Inventory | 8.9% | 2,470 | 2,268 | 2,126 | 2,348 | 3,153 | 3,488 | 4,664 | 4,679 | 4,462 | 4,649 | 5,087 | 4,679 | 5,304 | 5,385 | 4,769 | 3,649 | 2,562 | 2,128 | 2,314 | 2,040 | 1,864 |
Net PPE | 72.7% | 152 | 88.00 | 98.00 | 107 | 116 | 128 | 450 | 384 | 72.00 | 382 | 303 | 311 | 295 | 302 | 296 | 76.00 | 81.00 | 85.00 | 89.00 | 97.00 | 91.00 |
Goodwill | 5.4% | 800 | 759 | 800 | 759 | 759 | 800 | 759 | 800 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 748 |
Liabilities | 52.5% | 3,503 | 2,297 | 1,731 | 2,033 | 2,118 | 1,754 | 2,472 | 2,126 | 2,901 | 2,490 | 3,000 | 2,399 | 2,937 | 3,802 | 4,373 | 4,658 | 3,940 | 4,832 | 5,208 | 4,534 | 3,760 |
Current Liabilities | 15.6% | 2,113 | 1,828 | 1,197 | 1,415 | 1,412 | 1,551 | 2,111 | 1,748 | 2,390 | 1,823 | 2,170 | 1,408 | 1,325 | 2,379 | 2,765 | 3,108 | 2,428 | 3,116 | 3,292 | 3,110 | 2,654 |
Shareholder's Equity | -3.1% | 8,358 | 8,622 | 8,655 | 8,894 | 5,592 | 9,581 | 12,481 | 13,402 | 14,749 | 15,330 | 14,991 | 15,537 | 15,573 | 11,440 | 12,276 | 13,636 | 7,689 | 6,722 | 6,806 | 5,604 | 6,798 |
Retained Earnings | -0.5% | -144,400 | -143,752 | -143,570 | -143,137 | -142,831 | -142,000 | -138,800 | -137,700 | -135,725 | -134,700 | -133,500 | -132,395 | -131,858 | -131,100 | -130,087 | -128,430 | -127,332 | -127,188 | -126,444 | -125,502 | -124,153 |
Additional Paid-In Capital | 0.3% | 152,754 | 152,364 | 152,215 | 152,021 | 148,413 | 148,275 | 148,040 | 147,781 | 147,346 | 146,883 | 145,378 | 144,801 | 144,296 | 139,410 | 139,243 | 138,953 | 131,934 | 130,830 | 130,169 | 127,974 | 127,873 |
Shares Outstanding | 0.6% | 10,544 | 10,485 | 10,485 | 10,485 | 10,297 | 10,278 | 10,265 | 10,214 | 10,258 | 10,045 | 9,943 | 9,883 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | 3,289 | 3,279 | 3,260 | 3,242 | 3,054 | 3,054 | 3,054 | 3,053 | 3,051 | 3,052 | 3,046 | 3,040 | 3,014 | 3,009 | 3,003 | 3,000 | 3,000 |
Float | - | - | - | - | - | - | - | 9,879 | - | - | - | 60,900 | - | - | - | 43,900 | - | - | - | 17,800 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -147.0% | -264 | 562 | 226 | 276 | -195 | -170 | -1,072 | -1,797 | -335 | -910 | -117 | -55.00 | -1,526 | -1,817 | -1,720 | -1,840 | 364 | -614 | -1,329 | -697 | -528 |
Share Based Compensation | 161.7% | 390 | 149 | 194 | 319 | 179 | 254 | 277 | 272 | 434 | 268 | 281 | 276 | 206 | 172 | 179 | 222 | 670 | 354 | 150 | 158 | 397 |
Cashflow From Investing | - | - | - | - | - | - | - | -103 | -34.00 | - | -62.00 | - | -23.00 | - | -13.00 | - | - | - | -14.00 | - | -137 | - |
Cashflow From Financing | -Infinity% | -3.00 | - | -2.00 | -74.00 | -111 | -69.00 | -67.00 | 281 | -37.00 | 46.00 | 231 | -3.00 | 4,615 | -65.00 | 28.00 | 6,638 | -55.00 | 171 | 2,038 | -137 | 778 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Net revenue: | ||
Total net revenues | $ 14,238 | $ 9,975 |
Cost of goods sold | 5,833 | 5,244 |
Gross Margin | 8,405 | 4,731 |
Operating expenses: | ||
Research and development | 873 | 1,255 |
Depreciation and amortization | 214 | 218 |
Selling, general and administrative | 8,911 | 7,593 |
Total operating expenses | 9,998 | 9,066 |
Operating loss from continuing operations | (1,593) | (4,335) |
Other (expense) income: | ||
Interest expense | (2) | (20) |
Interest income | 64 | 14 |
Other (expense) income, net | (44) | 64 |
Total other income: | 18 | 58 |
Loss from continuing operations | (1,575) | (4,277) |
Net loss from discontinued operations | (2,829) | |
Net loss | (1,575) | (7,106) |
Less: undeclared deemed dividend attributable to noncontrolling interest | (276) | |
Net loss attributable to Nephros, Inc. shareholders | $ (1,575) | $ (7,382) |
Net loss per common share, basic from continuing operations | $ (0.15) | $ (0.42) |
Net loss per common share, diluted from continuing operations | (0.15) | (0.42) |
Net loss per common share, basic from discontinued operations | (0.28) | |
Net loss per common share, diluted from discontinued operations | (0.28) | |
Net loss per common share, basic | (0.15) | (0.70) |
Net loss per common share, diluted | (0.15) | (0.70) |
Net loss per common share, basic, attributable to continuing noncontrolling interest | (0.03) | |
Net loss per common share, diluted, attributable to continuing noncontrolling interest | (0.03) | |
Net loss per common share, basic, attributable to Nephros, Inc, shareholders | (0.15) | (0.73) |
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders | $ (0.15) | $ (0.73) |
Weighted average common shares outstanding, basic | 10,386,018 | 10,297,134 |
Weighted average common shares outstanding, diluted | 10,386,018 | 10,297,134 |
Comprehensive loss: | ||
Other comprehensive loss, foreign currency translation adjustments, net of tax | $ (14) | |
Comprehensive loss | (1,575) | (7,120) |
Comprehensive loss attributable to continuing noncontrolling interest | (276) | |
Comprehensive loss attributable to Nephros, Inc. shareholders | (1,575) | (7,396) |
Product [Member] | ||
Net revenue: | ||
Total net revenues | 14,110 | 9,929 |
Royalty And Other Revenues [Member] | ||
Net revenue: | ||
Total net revenues | $ 128 | $ 46 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,307 | $ 3,634 |
Accounts receivable, net | 1,496 | 1,286 |
Inventory | 2,470 | 3,153 |
Prepaid expenses and other current assets | 132 | 188 |
Total current assets | 8,405 | 8,261 |
Property and equipment, net | 152 | 116 |
Lease right-of-use assets | 1,807 | 984 |
Intangible assets, net | 381 | 423 |
Goodwill | 759 | 759 |
License and supply agreement, net | 271 | 402 |
Other assets | 86 | 54 |
TOTAL ASSETS | 11,861 | 10,999 |
Current liabilities: | ||
Current portion of secured note payable | 71 | |
Accounts payable | 873 | 740 |
Accrued expenses | 794 | 285 |
Current portion of lease liabilities | 446 | 316 |
Total current liabilities | 2,113 | 1,412 |
Equipment financing, net of current portion | 1 | |
Lease liabilities, net of current portion | 1,390 | 705 |
TOTAL LIABILITIES | 3,503 | 2,118 |
COMMITMENTS AND CONTINGENCIES (Note 17) | ||
STOCKHOLDERS’ EQUITY: | ||
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | ||
Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2023 and 2022; 10,543,675 and 10,297,429 shares issued and outstanding at December 31, 2023 and 2022, respectively | 10 | 10 |
Additional paid-in capital | 152,754 | 148,413 |
Accumulated deficit | (144,406) | (142,831) |
Subtotal | 8,358 | 5,592 |
Noncontrolling interest | 3,289 | |
TOTAL STOCKHOLDERS’ EQUITY | 8,358 | 8,881 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 11,861 | $ 10,999 |
 | Mr. Robert Banks |
---|---|
 | www.nephros.com |
 | 27 |